StonvexLoading…
StonvexStonvexStonvexCore line items from LUNG's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $90.50M | $83.79M | $68.67M | $53.66M |
Operating Income | $-53.66M | $-57.70M | $-61.94M | $-58.64M |
Net Income | $-54.00M | $-56.39M | $-60.84M | $-58.92M |
EPS (Diluted) | $-1.33 | $-1.44 | $-1.60 | $-1.59 |
Total Assets | $129.29M | $162.85M | $177.78M | $193.68M |
Total Liabilities | $75.17M | $77.04M | $59.47M | $39.67M |
Cash & Equivalents | $69.75M | $70.91M | $83.55M | $101.74M |
Free Cash Flow OCF − CapEx | $-32.83M | $-32.98M | $-38.42M | $-46.40M |
Shares Outstanding | 41.67M | 39.79M | 38.52M | 37.56M |